FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212078101> ?p ?o ?g. }

• W3212078101 endingPage "A914" @default.
• W3212078101 startingPage "A914" @default.
• W3212078101 abstract "Background Regulatory T cells (Tregs) are suppressive immune cells required for the maintenance of immune homeostasis, but tumor-infiltrating Tregs are known to suppress the antitumor immune system and promote tumor progression. Therefore, selective reduction of tumor-infiltrating Tregs is anticipated to reinvigorate antitumor immunity without inducing autoimmunity. S-531011 is a novel anti-human IgG1 antibody targeting human CCR8 (C-C motif chemokine receptor 8) which is selectively expressed in tumor-infiltrating Tregs, with both in vitro antibody dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells and neutralizing activity against CCL1-CCR8 signaling. Here, to evaluate antitumor activities and safety aspects of S-531011, we conducted non-clinical pharmacology studies of S-531011 using human CCR8 knock-in (KI) mice and human tissues. Methods S-531011 was administrated to CT26WT tumor-bearing hCCR8-KI mice, and the effect on the presence of tumor-infiltrating CCR8+ Treg and tumor growth were evaluated. We also investigated the antitumor efficacy of S-531011 in combination with anti-mouse PD-1 antibody. Next, human lung cancer tissues and human NK-cells were co-cultured, and the ex vivo ADCC against tumor-infiltrating Tregs by S-531011 was verified. We also incubated human peripheral blood-derived mononuclear cells (PBMC) from healthy individuals with S-531011 to investigate the effects on the proportion of Tregs in human PBMC. Results Intravenous administration of S-531011 to CT26WT tumor-bearing hCCR8-KI mice significantly reduced tumor-infiltrating CCR8+ Tregs and markedly suppressed tumor growth. Furthermore, the combined therapy of S-531011 with anti-mouse PD-1 antibody showed greater anti-tumor effect than monotherapy without any apparent side effects. Ex vivo ADCC studies using human lung cancer tissues and FCM analysis of CCR8 expression in tumor-infiltrating Tregs suggested that most of the tumor-infiltrating CCR8+ Tregs were depleted by S-531011. On the other hand, S-531011 didn’t reduce Tregs in human PBMC. Conclusions S-531011 is a promising drug which has a strong antitumor effect by depleting tumor-infiltrating CCR8+ Tregs, as a not only monotherapy but also combination therapy with other immune checkpoint inhibitors. Ethics Approval The present study was approved by the Institutional Ethics Committee of Osaka University Hospital (approved number: 13266-15) and Shionogi Co., Ltd. (approved number: 021-003). Animal studies were approved by the Institutional Animal Care and Use Committee (approved number: S20093D, S20197D and S20198D)." @default.
• W3212078101 created "2021-11-22" @default.
• W3212078101 creator A5004466997 @default.
• W3212078101 creator A5024225553 @default.
• W3212078101 creator A5038198190 @default.
• W3212078101 creator A5042599703 @default.
• W3212078101 creator A5045313293 @default.
• W3212078101 creator A5048527314 @default.
• W3212078101 creator A5051283453 @default.
• W3212078101 creator A5063890473 @default.
• W3212078101 creator A5076087584 @default.
• W3212078101 date "2021-11-01" @default.
• W3212078101 modified "2023-09-25" @default.
• W3212078101 title "873 S-531011, a novel anti-human CCR8 antibody: anti-tumor responses through depletion of tumor-infiltrating CCR8-positive Tregs" @default.
• W3212078101 doi "https://doi.org/10.1136/jitc-2021-sitc2021.873" @default.
• W3212078101 hasPublicationYear "2021" @default.
• W3212078101 type Work @default.
• W3212078101 sameAs 3212078101 @default.
• W3212078101 citedByCount "0" @default.
• W3212078101 crossrefType "journal-article" @default.
• W3212078101 hasAuthorship W3212078101A5004466997 @default.
• W3212078101 hasAuthorship W3212078101A5024225553 @default.
• W3212078101 hasAuthorship W3212078101A5038198190 @default.
• W3212078101 hasAuthorship W3212078101A5042599703 @default.
• W3212078101 hasAuthorship W3212078101A5045313293 @default.
• W3212078101 hasAuthorship W3212078101A5048527314 @default.
• W3212078101 hasAuthorship W3212078101A5051283453 @default.
• W3212078101 hasAuthorship W3212078101A5063890473 @default.
• W3212078101 hasAuthorship W3212078101A5076087584 @default.
• W3212078101 hasBestOaLocation W32120781011 @default.
• W3212078101 hasConcept C13373296 @default.
• W3212078101 hasConcept C137061746 @default.
• W3212078101 hasConcept C159654299 @default.
• W3212078101 hasConcept C202751555 @default.
• W3212078101 hasConcept C203014093 @default.
• W3212078101 hasConcept C2776156784 @default.
• W3212078101 hasConcept C2777701055 @default.
• W3212078101 hasConcept C2778326572 @default.
• W3212078101 hasConcept C40677261 @default.
• W3212078101 hasConcept C502942594 @default.
• W3212078101 hasConcept C542903549 @default.
• W3212078101 hasConcept C55493867 @default.
• W3212078101 hasConcept C71924100 @default.
• W3212078101 hasConcept C86803240 @default.
• W3212078101 hasConcept C8891405 @default.
• W3212078101 hasConceptScore W3212078101C13373296 @default.
• W3212078101 hasConceptScore W3212078101C137061746 @default.
• W3212078101 hasConceptScore W3212078101C159654299 @default.
• W3212078101 hasConceptScore W3212078101C202751555 @default.
• W3212078101 hasConceptScore W3212078101C203014093 @default.
• W3212078101 hasConceptScore W3212078101C2776156784 @default.
• W3212078101 hasConceptScore W3212078101C2777701055 @default.
• W3212078101 hasConceptScore W3212078101C2778326572 @default.
• W3212078101 hasConceptScore W3212078101C40677261 @default.
• W3212078101 hasConceptScore W3212078101C502942594 @default.
• W3212078101 hasConceptScore W3212078101C542903549 @default.
• W3212078101 hasConceptScore W3212078101C55493867 @default.
• W3212078101 hasConceptScore W3212078101C71924100 @default.
• W3212078101 hasConceptScore W3212078101C86803240 @default.
• W3212078101 hasConceptScore W3212078101C8891405 @default.
• W3212078101 hasIssue "Suppl 3" @default.
• W3212078101 hasLocation W32120781011 @default.
• W3212078101 hasOpenAccess W3212078101 @default.
• W3212078101 hasPrimaryLocation W32120781011 @default.
• W3212078101 hasRelatedWork W1479978113 @default.
• W3212078101 hasRelatedWork W2011324112 @default.
• W3212078101 hasRelatedWork W2026927141 @default.
• W3212078101 hasRelatedWork W2041538272 @default.
• W3212078101 hasRelatedWork W204820216 @default.
• W3212078101 hasRelatedWork W2115013237 @default.
• W3212078101 hasRelatedWork W2140647949 @default.
• W3212078101 hasRelatedWork W2396057067 @default.
• W3212078101 hasRelatedWork W2403627752 @default.
• W3212078101 hasRelatedWork W34744360 @default.
• W3212078101 hasVolume "9" @default.
• W3212078101 isParatext "false" @default.
• W3212078101 isRetracted "false" @default.
• W3212078101 magId "3212078101" @default.
• W3212078101 workType "article" @default.